medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 2

<< Back Next >>

Med Int Mex 2023; 39 (2)

Angiotensin II in vasodilatory shock: the fourth musketeer

Carrillo-Esper R, González-Martínez KI, Islas-Ávila RE, Salas-Zurita S

Language: Spanish
References: 24
Page: 301-312
PDF size: 311.54 Kb.


ABSTRACT

Hypotension is a key feature of shock. To date, no vasopressor has consistently been proven to be superior to the others in terms of clinical outcomes. Angiotensin II (ATII), an octapeptide, exerts its effects by binding to specific angiotensin receptors. In humans the major physiological effects are related to maintenance of hemodynamic stability and fluid and electrolyte regulation. In critical illness, especially in sepsis and other entities like COVID-19, physiological regulation of renin-angiotensin-aldosteron system and AT-II is disturbed. Recent studies demonstrated that AT-II is an effective and safe treatment for refractory hypotension in patients with vasodilatory shock, and may also have a role in cardiogenic and distributive shock and COVID-19.


REFERENCES

  1. Kimmoun A, Levy B. Angiotensin II: A new approach forrefractory shock management? Crit Care 2014; 18 (1): 1-2.https://doi.org/10.1186/s13054-014-0694-7

  2. Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW,Deane AM, Albertson TE. Angiotensin I and angiotensin IIconcentrations and their ratio in catecholamine-resistantvasodilatory shock. Crit Care 2020; 24 (1): 1-8. https://doi.org/10.1186/s13054-020-2733-x

  3. Mérida A, Leon FJ, Hernandez H. Regulación normal dela presión arterial sistémica. Rev Mex Cardiol 2004; 15(1): 30-41.

  4. Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A,Asfar P, Meziani F. Vascular hyporesponsiveness to vasopressorsin septic shock: From bench to bedside. Int CareMed 2010; 36 (12): 2019-2029. https://doi.org/10.1007/s00134-010-2045-8.

  5. Lumlertgul N, Ostermann M. Roles of angiotensin II asvasopressor in vasodilatory shock. Future Cardiology 2020;16 (6): 569-583. https://doi.org/10.2217/fca-2020-0019.

  6. Jia LZ, Xia CL. New insights and perspectives on intrarenalrenin-angiotensin system: Focus on intracrine/intracellularangiotensin II. Peptides 2011; 32 (7): 1551–1565.doi:10.1016/j.peptides.2011.05.012.

  7. Khanna A, Inglés SW, Wang XS, Jamón K, Tumlin J, SzerlipH, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdyMT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG,Ostermann M, Murugan R, Gong MN, Panwar R, H'stbackaJ, Favory R, Venkatesh B, Thompson BT, Bellomo R, JensenJ, K Sroll, Chawla LS, Investigadores ATHOS-3. AngiotensinII for the treatment of vasodilatory shock. N Engl JMed 2017; 377 (5): 419-430. https://doi.org/10.1056/nejmoa1704154.

  8. Chow JH, Galvagno SM, Tanaka KA, Mazzeffi MA, ChancerZ, Henderson R, McCurdy MT. When all else fails: Novel useof angiotensin II for vasodilatory shock: A case report. A&APractice 2018; 11 (7): 175-180. https://doi.org/10.1213/XAA.0000000000000775

  9. Mori J, Zhang L, Oudit GY, Lopaschuk GD, Impact of therenin–angiotensin system on cardiac energy metabolismin heart failure. J Mol Cell Cardiol 2013. http://dx.doi.org/10.1016/j.yjmcc.2013.07.010.

  10. Wakefield BJ, Sacha GL, Khanna AK. Vasodilatory shockin the ICU and the role of angiotensin II. Curr Opin CritCare 2018; 24 (4): 277-285. https://doi.org/10.1097/MCC.0000000000000517.

  11. Senatore F, Jagadeesh G, Rose M, Pillai VC, Hariharan S, LiuQ, McDowell TY, Sapru MK, Southworth MR, StockbridgeN. FDA. FDA Approval of angiotensin II for the treatmentof hypotension in adults with distributive shock. Am J CardiovascDrugs 2019; 19 (1): 11-20. https://doi.org/10.1007/s40256-018-0297-9.

  12. Bissell BD, Browder K, McKenzie M, Flannery AH. A blastfrom the past: Revival of angiotensin II for vasodilatoryshock. Ann Pharmacother 2018; 52 (9): 920-927. https://doi.org/10.1177/1060028018767899.

  13. Bussard RL, Busse LW. Angiotensin II: a new therapeuticoption for vasodilatory shock. Ther Clin Risk Manag 2018;

  14. 14-1287. http://dx.doi.org/10.2147/TCRM.S150434.14. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, HoniqJ, Alotaibi Z, Seneff MG. Intravenous angiotensin II forthe treatment of high-output shock (ATHOS trial): A pilotstudy. Crit Care 2014; 18 (5): 1-9. https://doi.org/10.1186/s13054-014-0534-9.

  15. Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS,Busse LW, Kashani KB. Management of refractory vasodilatoryshock. Chest 2018; 154 (2): 416-426. https://doi.org/10.1016/j.chest.2017.12.021.

  16. Buchtele N, Schwameis M, Jilma B. Angiotensin II for thetreatment of vasodilatory shock: Enough data to considerangiotensin II safe? Crit Care 2018; 22 (1): 1-2. https://doi.org/10.1186/s13054-018-2006-0.

  17. Pak I, Chaudhry M, Stuczynski L, Linga K, Krishna M.Efficacy of novel synthetic angiotensin II in septic shock.Chest 2020; 158 (4): A699. https://doi.org/10.1016/j.chest.2020.08.656.

  18. Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW,Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, FinkelKW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS,Tidmarsh GF, Bellomo R. Outcomes in patients with vasodilatoryshock and renal replacement therapy treated with intravenousangiotensin II. Crit Care Med 2018; 46 (6): 949.957.https://doi.org/10.1097/CCM.0000000000003092.

  19. Busse LW, McCurdy MT, Ali O, Hall A, Chen H, OstermannM. The effect of angiotensin II on blood pressure in patientswith circulatory shock: A structured review of the literature.Crit Care 2017; 21 (1): 1-12. https://doi.org/10.1186/s13054-017-1896-6.

  20. Belletti A, Musu M, Silvetti S, Saleh O, Pasin L, Monaco F,et al. Non-adrenergic vasopressors in patients with or atrisk for vasodilatory shock. A systematic review and metaanalysisof randomized trials. PLoS ONE 2015; 10 (11):e0142605. doi: 10.1371/journal.pone.0142605.

  21. Chow JH, Mazzeffi MA, Mccurdy MT. Angiotensin II forthe treatment of COVID-19-related vasodilatory shock.Anesth Analg 2020; 102-105. https://doi.org/10.1213/ANE.0000000000004825.

  22. Wieruszewski PM, Wittwer ED, Kashani KB, Brown DR, ButlerSO, Clark AM, Cooper CJ, Davison DL, Gajic O, GunnersonKJ, Tendler R, Mara KC, Barreto EF. Angiotensin II infusionfor shock: A multicenter study of postmarketing use.Chest 2021; 159 (2): 596-605. https://doi.org/10.1016/j.chest.2020.08.2074.

  23. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC,Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM,Cook DJ, Presneill JJ, Ayers D, the VASST Investigators. Vasopressinversus norepinephrine infusion in patients withseptic shock. N Engl J Med 2008; 358 (9): 877-887. DOI:10.1056/NEJMoa067373.

  24. Eleuteri D, Montini L, Cutuli LS, Rossi C, Alcaro F, AntonelliM. Renin-angiotensin system dysregulation in critically illpatients with acute respiratory distress syndrome due toCOVID-19: a preliminary report. Crit Care 2021; 25: 91-93.https://doi.org/10.1186/s1304-021-03507-7.




2020     |     www.medigraphic.com